Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Tengion Inc (TNGNQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.00000 0.00000    0.00%
02/02 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.00000 / 0.00000
  • Day's Range: 0.00000 - 0.00000
Tengion Inc 0.00000 0.00000 0.00%

Tengion Inc Company Profile

 
Get an in-depth profile of Tengion Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

26

Equity Type

ORD

Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.

Contact Information

Address 3929 Westpoint Boulevard Suite G
Winston-Salem, 27103
United States
Phone 336-722-5855
Fax -
Web

Top Executives

Name Age Since Title
Alan B. Retik - - Member of Research & Development Advisory Board
Buddy D. Ratner - - Member of Research & Development Advisory Board
Nancy Bachrach - 2012 Member of Business Advisory Board
Victor J. Dzau 75 - Member of Research & Development Advisory Board
Alan J. Russell - - Member of Scientific Advisory Board
Richard J. Zeckhauser 80 - Member of Business Advisory Board
Arthur Leonard Caplan - - Member of Research & Development Advisory Board
Robert Nerem - - Member of Research & Development Advisory Board
William D. Schwieterman 63 - Member of Research & Development Advisory Board
Mark P. Schoenberg 63 - Member of Scientific Advisory Board
Prediman K. Shah - - Member of Scientific Advisory Board
Geeta S. Vemuri - - Board Observer
John L. Miclot 62 2011 Director
Richard E. Kuntz 64 2010 Director
Stephen F. Badylak - - Member of Research & Development Advisory Board
David I. Scheer 68 2003 Co-Founder & Chairman of the Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TNGNQ Comments

Write your thoughts about Tengion Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email